Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,185.88 +5.14 (+0.10%) Dow
38,873.97 +21.70 (+0.06%) Nasdaq
16,336.43 -12.82 (-0.08%) Bitcoin USD
63,225.64 +114.91 (+0.18%) CMC Crypto 200
1,307.87 -57.25 (-4.19%)
GSK May 2024 42.000 call
| Previous close | 0.9000 |
| Open | 2.2000 |
| Bid | 2.0500 |
| Ask | 2.2000 |
| Strike | 42.00 |
| Expiry date | 2024-05-31 |
| Day's range | 2.2000 - 2.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 26 |
GlobeNewswireBioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections
Insider MonkeyGSK plc (NYSE:GSK) Q1 2024 Earnings Call Transcript
GSK plc (NYSE:GSK) Q1 2024 Earnings Call Transcript May 4, 2024 GSK plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Nick Stone: Hello everyone. Welcome to today’s call and webcast. The presentation was sent to our distribution list by email, and […]
Simply Wall St.GSK First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GSK ( LON:GSK ) First Quarter 2024 Results Key Financial Results Revenue: UK£7.36b (up 5.9% from 1Q 2023). Net income...
